GLP-1 Medications Should Be Continued Before Cataract Surgery
For cataract surgery specifically, GLP-1 receptor agonists should be continued throughout the perioperative period without interruption. 1
Key Recommendation
The most recent multidisciplinary consensus statement from 2025 explicitly states that patients taking GLP-1 receptor agonists should continue these drugs before surgery 1. This represents the highest quality guidance available and reflects a pragmatic, evidence-based approach to perioperative management.
Why Cataract Surgery is Different
Cataract surgery is fundamentally distinct from procedures requiring general anesthesia or deep sedation:
- No aspiration risk: Cataract surgery is performed under topical or local anesthesia without airway instrumentation
- No fasting required: Patients can eat and drink normally before the procedure
- No gastric emptying concerns: The theoretical risk of delayed gastric emptying with GLP-1 RAs is irrelevant when no sedation or general anesthesia is used
The aspiration concerns that drive GLP-1 RA discontinuation recommendations for other surgeries simply do not apply to cataract procedures 1, 2.
Risk-Benefit Analysis
Continuing GLP-1 RAs provides clear benefits:
- Maintains glycemic control in diabetic patients
- Avoids metabolic disruption
- Prevents unnecessary medication interruption
- No added aspiration risk with topical/local anesthesia
Stopping GLP-1 RAs creates unnecessary risks:
- Worsened glycemic control for 1-3 weeks (depending on drug half-life)
- Potential metabolic decompensation
- No safety benefit for a procedure without aspiration risk
Important Caveats
If the cataract surgery plan changes to include:
- IV sedation or general anesthesia: Then apply standard perioperative GLP-1 RA management with full risk assessment and aspiration mitigation strategies 1
- Monitored anesthesia care with deep sedation: Consider the same precautions as general anesthesia
Context: When GLP-1 RAs Should Be Stopped
For procedures requiring general anesthesia or deep sedation, the 2024 guidelines suggest different approaches 2:
For weight loss patients: Hold for at least 3 half-lives (e.g., 3 weeks for weekly semaglutide) 2
For diabetic patients: Consult endocrinology regarding risks/benefits of holding, as prolonged cessation worsens glycemic control 2
However, the 2025 consensus represents an evolution toward continuing GLP-1 RAs even for general anesthesia cases, with implementation of aspiration risk mitigation strategies instead of routine discontinuation 1.
Clinical Pitfalls to Avoid
- Don't reflexively stop all medications before "surgery": Cataract procedures under topical anesthesia don't carry aspiration risk
- Don't confuse guidance for general anesthesia with local procedures: The aspiration concern is procedure-specific, not drug-specific
- Don't create metabolic harm without clinical benefit: Stopping GLP-1 RAs for cataract surgery provides no safety advantage
The evidence is clear: continue GLP-1 receptor agonists for cataract surgery performed under topical or local anesthesia. 1